Folate Receptor Alpha (FRα/FOLR1) in Cancer: Diagnostic, Prognostic or Predictive Biomarker? A Critical Review of Its Clinical Utility
- 1Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Powstańców Wlkp. 72, 70-111 Szczecin, Poland
Abstract
Folate receptor alpha (FRα) plays a key role in folate homeostasis. Folate is involved, among other processes, in nucleotide biosynthesis, and the marked difference between FRα expression in certain cancers and under physiological conditions gives this receptor potential as a cancer biomarker. However, the current state of knowledge points to a specific role for this marker and defines its potential place in cancer diagnosis and treatment. This review aims to critically evaluate the available evidence regarding the clinical utility of FRα. Analysis of the literature indicates that despite differences in expression, the sensitivity and specificity of FRα are insufficient for its use as a standalone diagnostic marker. In contrast, its potential as a prognostic marker is strongly dependent on cancer type. The strongest evidence of clinical utility concerns membranous FRα protein expression assessed by a validated immunohistochemical companion diagnostic assay for selecting patients with platinum-resistant ovarian cancer for mirvetuximab soravtansine treatment. In contrast, the predictive relevance of FRα for other targeted therapeutic strategies remains under investigation. Overall, FRα should be regarded as a clinically actionable biomarker in a defined therapeutic setting and as a promising, but not universally validated, diagnostic, prognostic, and predictive candidate in other oncological applications.
Related
- Integrated bulk and single-cell transcriptomic analyses with experimental validation identify PLOD1 as a diagnostic biomarker and TGF-β1-responsive profibrotic mediator in dupuytren’s disease
- Kynureninase Is a Prognostic Biomarker of Poor Survival and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
- Beyond Mesothelioma: From Diagnostic Biomarker to Therapeutic Opportunity—The Emerging Role of MTAP in Cancer
- Single-cell transcriptomic atlas of gastric cancer reveals malignant cell heterogeneity and nominates EMB as a candidate prognostic biomarker.
- Controversial membrane structure, independently verified after 22 years, is diagnostic and prognostic for cancer risk.
BibTeX
@article{kapczuk2026folate,
title = {{Folate Receptor Alpha (FRα/FOLR1) in Cancer: Diagnostic, Prognostic or Predictive Biomarker? A Critical Review of Its Clinical Utility}},
author = {Patrycja Kapczuk and Zuzanna Marcinowska and Maciej Kołodziejczak and Donata Szubert},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219720},
url = {https://www.mdpi.com/1422-0067/27/21/9720},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Folate Receptor Alpha (FRα/FOLR1) in Cancer: Diagnostic, Prognostic or Predictive Biomarker? A Critical Review of Its Clinical Utility
AU - Patrycja Kapczuk
AU - Zuzanna Marcinowska
AU - Maciej Kołodziejczak
AU - Donata Szubert
PY - 2026
DA - 2026/10/29
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219720
UR - https://www.mdpi.com/1422-0067/27/21/9720
AB - Folate receptor alpha (FRα) plays a key role in folate homeostasis. Folate is involved, among other processes, in nucleotide biosynthesis, and the marked difference between FRα expression in certain cancers and under physiological conditions gives this receptor potential as a cancer biomarker. However, the current state of knowledge points to a specific role for this marker and defines its potential place in cancer diagnosis and treatment. This review aims to critically evaluate the available evidence regarding the clinical utility of FRα. Analysis of the literature indicates that despite differences in expression, the sensitivity and specificity of FRα are insufficient for its use as a standalone diagnostic marker. In contrast, its potential as a prognostic marker is strongly dependent on cancer type. The strongest evidence of clinical utility concerns membranous FRα protein expression assessed by a validated immunohistochemical companion diagnostic assay for selecting patients with platinum-resistant ovarian cancer for mirvetuximab soravtansine treatment. In contrast, the predictive relevance of FRα for other targeted therapeutic strategies remains under investigation. Overall, FRα should be regarded as a clinically actionable biomarker in a defined therapeutic setting and as a promising, but not universally validated, diagnostic, prognostic, and predictive candidate in other oncological applications.
SN - 1422-0067
ER -